脑脊液
多发性硬化
免疫球蛋白轻链
生物标志物
医学
病理
化学
免疫学
抗体
生物化学
作者
Robert L. Hendricks,Dana Baker,Jochen Brumm,Teresa Davancaze,Chris Harp,Ann Herman,H.‐Christian von Büdingen,Michael J. Townsend,Saloumeh K Fischer
出处
期刊:Bioanalysis
[Newlands Press Ltd]
日期:2019-08-01
卷期号:11 (15): 1405-1418
被引量:65
标识
DOI:10.4155/bio-2019-0163
摘要
Background: Neurofilament light (NfL) chain is an established cerebrospinal fluid (CSF) biomarker for neuroaxonal injury. The highly sensitive Quanterix Simoa™ platform is evaluated for NfL measurement in both CSF and blood. There is a need to link historical ELISA data that use bovine NfL to that of Simoa using a recombinant human (rhuman) NfL standard. Results/Methodology: The Simoa NF-light ® Advantage Kit was validated for CSF and qualified for serum and plasma, using both rhuman and bovine NfL calibrators. Matched CSF, serum and plasma samples from 112 multiple sclerosis patients were analyzed using both calibrators. Conclusion: In multiple sclerosis, there is a good correlation between blood and CSF NfL levels. A conversion factor of approximately 5:1 was established between bovine and rhuman NfL calibrators.
科研通智能强力驱动
Strongly Powered by AbleSci AI